Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Panel Continues To Push For Obesity CV Guidance As It Backs Contrave Approval

Dec 13 2010

• By Cathy Dombrowski

Related Content

The Skinny On The Obesity Drug Advisory Committees: A Look At The Panelists' Votes

Dec 13 2010

Orexigen Offers Robust <i>Contrave</i> Risk Plan To Monitor For Safety Concerns

Dec 13 2010

Positive Panel Recommendation For Contrave Could Change Obesity Drug Game

Dec 13 2010

FDA Pressed At <i>Meridia</i> Committee Review To Finalize Obesity Drug Guidance

Sep 20 2010

REMS Cannot Save Abbott's Obesity Drug Meridia In Face Of Cardiovascular Issues

Oct 08 2010

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window